Kornimate/medical-research-clean huggingface dataset:
single ventricle outcome

Conditions: Heart Disease, Congenital; Single Ventricle; Hypoplastic Left Heart Syndrome

Summary: the objective of this research proposal is to perform an ongoing single institution prospective clinical trial examining the overall clinical outcome of children with single ventricle physiology.

congenital disease is the most common cause for infant death from a birth defect. approximately 30,000 infants are born each year with congenital heart defects.over one-third of those babies will require cardiac surgery. a particularly lethal cardiac defect is one with single ventricle physiology. the objective of this research proposal is to perform an ongoing single institution prospective clinical trial examining the overall clinical outcome of children with single ventricle physiology.

Eligibility criteria:
inclusion criteria: * all patients with single ventricle physiology scheduled for ultimate fontan surgical palliation at children's healthcare of atlanta will be eligible. * all subjects must sign informed consent prior to enrollment in study.

Keywords: heart disease, congenital single ventricle hypoplastic left heart syndrome
youth-nominated support team intervention for suicidal adolescents

Conditions: Suicide, Attempted

Summary: this study will attempt to improve treatment adherence and reduce suicide risk among adolescents who are at risk for attempting suicide.

despite substantial knowledge about adolescent suicide risk factors, few studies have been conducted to identify effective interventions for suicidal adolescents. youth-nominated support team (yst) is an intervention designed to help suicidal adolescents after hospitalization. it is a psychoeducational social network intervention that targets poor treatment adherence and difficulties with social support. yst is designed to be a supplement to traditional or usual treatments. participants are randomly assigned to receive either treatment as usual (tau) or tau plus yst for 3 months. adolescents who receive tau plus yst nominate three or four adults from their family, school, and community settings to function as support persons. the support persons participate in a psychoeducation session that focuses on the adolescent's psychiatric disorder(s), individualized treatment plan, importance of treatment adherence, and suicide risk factors. they also maintain regular contact with the adolescent to support treatment adherence and progress toward treatment goals. adolescents have assessments at 6 weeks, 3 months, 6 months, and 12 months. internalizing behavior problems, perceived social support, treatment adherence, adaptive functioning, severity of depression and anxiety, severity and frequency of suicidal thoughts, and suicide attempts are assessed.

Eligibility criteria:
inclusion criteria: * hospitalization in a participating psychiatric facility * suicidal ideation, intent, or attempt exclusion criteria: * severe physical or cognitive impairment that makes informed consent, nominations, or participation in assessments impossible

Keywords: suicide adolescence
intravenous magnesium for sickle cell vasoocclusive crisis

Conditions: Sickle Cell Disease

Summary: the purpose of this study is to determine the safety and efficacy of intravenous magnesium in shortening the duration of a pain crisis and to determine the health-related quality of life and short term outcomes of children treated with intravenous magnesium during an acute pain crisis.

it is well known that children with sickle cell disease are at risk for acute pain crises. the usual treatment for these pain crises, intravenous fluids and pain medicines such as morphine, has changed little over the past three decades. in a pilot study, the addition of intravenous magnesium to standard therapy decreased length of stay; however, this study was not randomized, not blinded, not placebo-controlled, and not adequately powered to assess safety. we will conduct a multi-center, randomized, double-blind, placebo controlled trial of about 208 children, ages 4-21 years. patients will be randomized to receive intravenous magnesium sulfate or placebo every 8 hours for a total of 6 doses, or until discharge. patients will return for a routine clinic visit up to 3 months after discharge for a baseline assessment. patients will also complete health-related quality of life measures at 4 timepoints throughout the study.

Eligibility criteria:
inclusion criteria: * age 4-21 years, inclusive * sickle cell anemia (hb ss) or sickle beta zero thalassemia disease (hb sβ°) * failed intravenous opioid pain management in the emergency department prior to the decision to admit the patient * admitted to the inpatient unit for sickle cell pain crisis exclusion criteria: * patient received more than 12 hours of intravenous pain medication prior to enrollment * previous enrollment in this study (only one admission per child is eligible) * history of allergy/intolerance to both intravenous morphine and hydromorphone * known other cause for pain (avascular necrosis, gall bladder disease, priapism, etc.) * patient with greater than 10 admissions for pain crisis in the past year * patient maintained on daily opioids or chronic transfusions for chronic sickle cell pain * transfusion within the previous two months * known kidney or liver failure (elevation of liver function tests does not warrant exclusion) * known pulmonary hypertension * pregnancy * diagnosis of bacterial infection, fever ≥39.5°c, acute chest syndrome, hemodynamic instability or sepsis * current oral magnesium supplementation or current enrollment in another therapeutic study protocol * previously diagnosed clinical stroke * current or planned use of neuromuscular blocker, nifedipine, ritodrine, or terbutaline * allergy to magnesium sulfate * discharge from an inpatient unit within 72 hours of arrival in the emergency department for the current pain crisis

Keywords: sickle cell disease magnesium sulfate pediatric
rapid screening test for covid-19 antibodies in healthcare workers

Conditions: Covid-19 Immune Status of Healthcare Workers

Summary: the study objectives were to assess 1/the immune status of healthcare professionals with suggestive symptomatology of covid-19 infection and 2/the sensitivity and specificity of aaz rapid test by comparing it with a serological elisa test. an open-label, monocentric, prospective, non-randomized study, is conducted, including 50 hospital healthcare professionals and 50 private health professionals. knowledge of serostatus will achieve the implementation of a strategy of management of patients according to specific immunity of health professionals


Eligibility criteria:
inclusion criteria: * healthcare professionals with symptoms suggestive of covid-19 infection exclusion criteria: * any other subject * pregnant women * protected adult
perioperative lidocaine administration in thoracoscopic surgery for improved postoperative pain control

Conditions: Postoperative Pain

Summary: placebo-controlled study to analyze the effect of perioperative intravenous lidocaine administration on total morphine consumption (tmc) and on pain intensity in thoracoscopic surgery .

thoracoscopy (thoracic surgery) is a video-assisted minimally invasive operation in thoracic surgery, which is associated with pain after surgery. trial drug lidocaine is approved as pain medication. this placebo-controlled study analyzes the effect of perioperative intravenous lidocaine administration on total morphine consumption (tmc) and on pain intensity in thoracoscopic surgery . half of the patients will receive nacl 0.9% (a saline solution without active ingredient) instead of lidocaine.

Eligibility criteria:
inclusion criteria: * patients undergoing video-assisted thoracoscopic procedures under general anaesthesia. * american society of anesthesiologists (asa) physical status classes i to iii * age ≥ 18 years * patient informed consent exclusion criteria: * contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product * contraindications to self-administration of opioids * women who are pregnant or breast feeding * steroid therapy * chronic pain therapy * atrioventricular block grade ii to iii * congestive heart failure * liver insufficiency * known or suspected non-compliance, drug or alcohol abuse * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia * participation in another study with investigational drug within the 30 days preceding and during the present study, * enrolment of the investigator, his/her family members, employees and other dependent persons

Keywords: thoracoscopic surgery perioperative intravenous lidocaine administration lidocaine
tailoring an internet delivered cognitive behavioral therapy for insomnia in persons with inflammatory rheumatic diseases

Conditions: Insomnia

Summary: cognitive behavioral therapy for insomnia (cbti) is considered a first-line treatment for insomnia. access to this treatment option is limited therefore the investigators have been developing an internet delivered cognitive behavioral therapy for insomnia (i-cbti) to help overcome accessibility barriers. the purpose of this study is to pilot test a tailored internet-delivered cognitive behavioral therapy for insomnia (i-cbti) intervention for persons with inflammatory rheumatic diseases showing symptoms of insomnia.


Eligibility criteria:
inclusion criteria: * self-reported physician diagnosis of one or more of the following inflammatory rheumatic diseases: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or other spondyloarthropathies, systemic lupus erythematosus * have an e-mail address and internet access * speak and read english or french * resident of canada and living in canada for the duration of the trial * have insomnia symptoms ( score ≥8 on the insomnia severity index (isi) ) exclusion criteria: * self-reported sleep disorder diagnosed by a physician other than insomnia (e.g. obstructive sleep apnea) * severe psychiatric disorder (e.g. schizophrenia, bipolar disorder) or neurological disorders (e.g diagnosis of dementia, parkinson disease, epilepsy) * already involved in psychotherapy addressing sleep difficulties * shift work in the past 3 months or next 6 months
mrcp diagnoses ehcc better when combined dwi

Conditions: Biliary Tract Neoplasm; Cholangiocarcinoma

Summary: researching the diagnostic significance of biliary tract neoplasm under combining dwi sequence with mrcp versus mrcp only separately.

the purpose of the study is to evaluate the usefulness of diffusion weighted imaging(dwi) combined with mrcp of 3.0t magnetic resonance imaging (mri) in the evaluation of suspected malignant bile duct diseases. people with suspected biliary tract neoplasm based on clinical symptoms (such as jaundice and thinness with unknown reasons) and ca-199 value raises are included.diagnosis divided into two steps: the first one，only provide conventional mr sequences and mrcp images to make a diagnosis; the second step,provide the dwi images additionally, combining the image data before to make a diagnosis. hypothesis is that dwi sequence should be regularly added into mrcp examination for improving diagnosis rate of biliary tract neoplasm.

Eligibility criteria:
inclusion criteria: * informed consent * suspected biliary tract neoplasm based on clinical symptoms(such as jaundice and thinness with unknown reasons)and ca-199 raises（\>37u/ml） * no evidence of clinical symptoms or ca-199 increase by non-bile duct cancerous factors(hepatitis,cholangeitis,stones) * age ≥ 16 exclusion criteria: * previous biliary tract neoplasm surgery * contraindication for mri (such as pacemaker or inner ear implant) * claustrophobia * age \< 16

Keywords: biliary tract neoplasm cholangiocarcinoma diffusion magnetic resonance imaging magnetic resonance imaging magnetic resonance cholangiopancreatography
safety study of avastin used as adjunctive therapy in pterygium surgery

Conditions: Pterygium

Summary: this study will evaluate the efficacy and safety of the use of bevacizumab (avastin) as an adjunctive medication during pterygium surgery in preventing pterygium recurrence. a pterygium is a white fleshy growth on the surface of the eye, which can be removed surgically. however, after surgical removal, pterygia can recur. one way of minimizing recurrence is by applying a medication called mitomycin c to the surface of the eye during pterygium surgery. however, mitomycin is associated with certain side effects, such as thinning of the eye wall and poor wound healing. bevacizumab has a different mechanism of action and there is some evidence that it may be useful in preventing pterygium recurrence. in this study, the safety and efficacy of adjunctive intraoperative use of bevacizumab and mitomycin c for preventing pterygium recurrence will be directly compared.


Eligibility criteria:
inclusion criteria: * age 18 to 80 * presence of primary or recurrent pterygium * pterygium grows greater than 2mm onto cornea from limbus (using slit lamp light beam to measure size) * pterygium is inducing astigmatism greater than 1 diopter compared to the fellow eye (to be determined by automated keratometry and manifest refraction) * the pterygium is symptomatic (irritation, inflammation, strabismus, decreased visual acuity) exclusion criteria: * age less than 18 * age greater than 80 * any systemic rheumatologic or autoimmune disorder (autoimmune hepatitis, bullous pemphigoid, celiac disease, crohn's disease, dermatomyositis, graves' disease, hashimoto's thyroiditis, systemic lupus erythematosus, mixed connective tissue disease, pemphigus vulgaris, psoriasis, polymyositis, rheumatoid arthritis, scleroderma, sjogren's disease, ulcerative colitis, vasculitis, wegener's granulomatosus) * women who are potentially child-bearing (no possibility of pregnancy for at least one month after surgery) * any use within the past two months of topical eye drops other than artificial tears in the study eye * any previous intravitreal injections of any medication in the study eye * any previous use of systemic, topical, or intravitreal bevacizumab in either eye * any history of subconjunctival injections in the study eye within the past year * any history of scleral or corneal laceration in the study eye * ocular surgery within the past 3 months in the study eye * history of scleral buckle placement in the study eye * history of glaucoma
virtual rehabilitation and conventional therapeutic exercises in the treatment of individuals post stroke

Conditions: Stroke; Cerebrovascular Disorders

Summary: the purpose of this study is to determine the effects of the use the nintendo wii® (nw) and conventional therapeutic exercises in the rehabilitation of balance and gait of the post-stroke patients and the impact on quality of life.

this randomised clinical trial (rct) has longitudinal and prospective feature, held at the neurosciences clinic located at the clinic professor francisco magalhães neto the hupes complex / federal university of bahia from june 2015 until june 2017. in the initial evaluation were obtained by a trained examiner and blinded to the allocation of participants, all personal data of all patients, as well as evaluations of balance, gait, and quality of life through specific validated scales: 1. berg balance scale (bbs); 2. tinetti gait scale (tgs) 3. quality of life scale specific for stroke (qlsss) ; the investigators employ a program of conventional therapeutic exercises and virtual rehabilitation with nw, for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).

Eligibility criteria:
inclusion criteria: * age between 18 and 80 years, of both sexes; clinical diagnosis of stroke confirmed by neurological assessment report or neuroimaging; * a stroke at least 6 months prior to the study * the ability to walk independently with or without an assistive device; * absence of visual or auditory deficits as reported by the subject. exclusion criteria: * score \<24 on the mini mental state examination; * other associated neurological conditions; * other orthopedic injuries that could impair mobility and make the execution of the proposed activity impossible; * participation in other physical rehabilitation programs.

Keywords: stroke hemiparesis physical therapy virtual reality exposure therapy video games
efficacy and safety evaluation of anti-cd20 monoclonal antibody combined with azathioprine and corticosteroids in the treatment of pemphigus vulgaris

Conditions: Pemphigus; Pemphigus Vulgaris (PV)

Summary: a prospective cohort study was conducted, following patients for 36 weeks from january 1, 2023, to april 30, 2024. patients meeting the diagnostic criteria were nonrandomly grouped based on screening results. the primary endpoints were time to disease control and skin healing. secondary endpoints included complete remission rates, relapse rates, corticosteroid doses, pemphigus disease area index (pdai), dermatology life quality index (dlqi), visual analogue scale (vas) pain scores, cd19+ b cell percentages, desmoglein-specific antibodies, and adverse events.


Eligibility criteria:
inclusion criteria: - patients with moderate to severe pemphigus who have poor control of previous external medications and require systemic treatment have a pdai (pemphigus area and activity score) greater than 9 points. exclusion criteria: * patients with serious basic diseases, with hepatitis b and three positive cases, and with a history of immunoglobulin related diseases.

Keywords: pemphigus
a biologic joint replacement strategy for knee trauma and post-traumatic osteoarthritis

Conditions: Knee Osteoarthritis; Post-traumatic Osteoarthritis

Summary: participants will be enrolled in a prospective clinical trial to assess outcomes in 2 cohorts of patients undergoing unicompartmental versus more extensive biologic oca transplantation of the knee using mopstm-preserved allografts (including menisci), anatomically-shaped allografts, autogenous bone marrow aspirate concentrate (bmc)-treated donor bone, and treatment-specific postoperative rehabilitation.

with irb approval, patients will be enrolled in a prospective clinical trial to assess outcomes in 2 cohorts of patients undergoing unicompartmental versus more extensive biologic oca transplantation of the knee using mopstm-preserved allografts (including menisci), anatomically-shaped allografts, autogenous bone marrow aspirate concentrate (bmc)-treated donor bone, and treatment-specific postoperative rehabilitation. demographic and operative data will be collected. outcome assessments will include vas pain, ikdc, sane, tegner and promis mobility for knee at 6 months and yearly after surgery. in addition, serial limb alignment measurements, ultrasonographic assessments of meniscal location and integrity, quantitative mris for cartilage composition, and serum and urine biomarkers for treatment monitoring will be performed. all complications and re-operations will be recorded. oca survival will be determined based on maintenance of acceptable levels of pain and function and/or need for revision surgery or total knee arthroplasty.

Eligibility criteria:
inclusion criteria: * grade iv changes in the articular cartilage of the femoral condyle and tibial plateau and meniscal pathology in the medial or lateral femorotibial joint (unicompartmental) or unicompartmental and other femoral condyle, tibial plateau, trochlea and/or patella. * between the age of 18-55 exclusion criteria: * acute injury to any other part of the affected lower extremity * inability to comply with protocol * bmi greater than 40 * the subject is either pregnant or a prisoner * currently involved in worker's compensation case at the time of enrollment

Keywords: knee pain
edinburgh cognitive and behavioural amyotrophic lateral sclerosis screen in norway: a validation study

Conditions: Amyotrophic Lateral Sclerosis; Cognitive Impairment

Summary: cognitive impairment is present in about 30-50% of the patients with amyotrophic lateral sclerosis (als). suitable screening tools are available, but none of these are evaluated in a norwegian population.

screening of cognitive and behavioral impairment is a distinct recommendation in als-specific health-care. thus, a rapid screening tool valid for use in norway is urgent. however, cognitive assessment for patients with als can be difficult due to the complexity of cognitive impairment, as well as motor challenges with writing, drawing and speaking. therefore, only als-specific, multi domain screening instruments with integrated behavioral sections should be used. internationally, the edinburgh cognitive and behavioral amyotrophic lateral sclerosis screen (ecas), is recommended for the purpose. besides being quick and easy to administer, the ecas is shown to be sensitive and have high specificity to als-specific dysfunction and behavioral changes. the introduction of ecas has probably contributed to a more nuanced picture of cognitive impairment in als than previously assumed. therefore the ecas has been translated and culturally adapted into norwegian (ecas-n). based on scores from healthy people, norwegian age- and educational-adjusted norms for verbal fluency (n=277) and cut-off-scores (n=85) for abnormal findings are established. however, further investigation of psychometric properties of the ecas-n is needed. the objectives of the study are: 1. to investigate if the ecas-n reflect cognitive impairment (internal consistency), and is robust to measurement errors due to different times of testing (test-retest reliability) and different raters (interrater reliability) 2. to investigate if the ecas-n can be used to distinguish between people with als-specific cognitive impairment, and those who do not have cognitive impairment, and those who have cognitive impairment due to other disorders (construct validity).

Eligibility criteria:
inclusion criteria: * voluntary informed consent * native norwegian speaker * aged between 35 and 85 years old (only for controls) exclusion criteria: * great difficulties in writing og reading * comorbid medical history * neurological disorders others than als * psychiatric history of importance to cognitive function

Keywords: amyotrophic lateral sclerosis cognitive screening validation